Ciro R. Rinaldi

799 total citations
37 papers, 438 citations indexed

About

Ciro R. Rinaldi is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Ciro R. Rinaldi has authored 37 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 22 papers in Hematology and 10 papers in Molecular Biology. Recurrent topics in Ciro R. Rinaldi's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers), Acute Myeloid Leukemia Research (14 papers) and Phagocytosis and Immune Regulation (9 papers). Ciro R. Rinaldi is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers), Acute Myeloid Leukemia Research (14 papers) and Phagocytosis and Immune Regulation (9 papers). Ciro R. Rinaldi collaborates with scholars based in United Kingdom, Italy and United States. Ciro R. Rinaldi's co-authors include Giuseppina Nucifora, Leopoldo Laricchia‐Robbio, Donglan Li, Kislay K. Sinha, Vitalyi Senyuk, Soumen Chakraborty, Bruno Rotoli, Vincenzo Martinelli, Deborah Hunter and Jenny Byrne and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ciro R. Rinaldi

29 papers receiving 430 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ciro R. Rinaldi United Kingdom 12 241 217 150 67 57 37 438
Karen Lambie Canada 10 237 1.0× 160 0.7× 121 0.8× 37 0.6× 95 1.7× 12 406
Monika J. Stankiewicz United States 7 171 0.7× 171 0.8× 90 0.6× 56 0.8× 28 0.5× 11 336
Paulina M. H. van Strien Netherlands 7 137 0.6× 194 0.9× 135 0.9× 43 0.6× 46 0.8× 11 400
Mónica Ventura Ferreira Germany 6 191 0.8× 199 0.9× 168 1.1× 49 0.7× 50 0.9× 7 431
Cristina Robledo Spain 13 174 0.7× 132 0.6× 163 1.1× 18 0.3× 81 1.4× 27 399
Anke K. Bergmann Germany 12 113 0.5× 244 1.1× 128 0.9× 79 1.2× 77 1.4× 34 524
Katarina Reinhardt Germany 13 318 1.3× 211 1.0× 80 0.5× 37 0.6× 67 1.2× 20 551
Stephanie Wallner Austria 7 144 0.6× 108 0.5× 157 1.0× 73 1.1× 124 2.2× 7 424
Axel Karow Germany 8 493 2.0× 303 1.4× 470 3.1× 163 2.4× 40 0.7× 22 692
Jun Mo United States 10 168 0.7× 235 1.1× 49 0.3× 22 0.3× 80 1.4× 26 480

Countries citing papers authored by Ciro R. Rinaldi

Since Specialization
Citations

This map shows the geographic impact of Ciro R. Rinaldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ciro R. Rinaldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ciro R. Rinaldi more than expected).

Fields of papers citing papers by Ciro R. Rinaldi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ciro R. Rinaldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ciro R. Rinaldi. The network helps show where Ciro R. Rinaldi may publish in the future.

Co-authorship network of co-authors of Ciro R. Rinaldi

This figure shows the co-authorship network connecting the top 25 collaborators of Ciro R. Rinaldi. A scholar is included among the top collaborators of Ciro R. Rinaldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ciro R. Rinaldi. Ciro R. Rinaldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rinaldi, Ciro R., et al.. (2023). Effects of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.. Journal of Clinical Oncology. 41(16_suppl). 7064–7064.
3.
Rinaldi, Ciro R., et al.. (2023). Expression of CD47 and CALR in myeloproliferative neoplasms: Potential new therapeutical targets.. Journal of Clinical Oncology. 41(16_suppl). e19079–e19079.
4.
Melo‐Cardenas, Johanna, Jeremy Chase Crawford, Sandeep Gurbuxani, et al.. (2022). IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood. 140(26). 2805–2817. 35 indexed citations
5.
Mead, Adam J., Nauman M. Butt, Ciro R. Rinaldi, et al.. (2022). A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study. Therapeutic Advances in Hematology. 13. 1554002247–1554002247. 4 indexed citations
6.
Rinaldi, Ciro R., et al.. (2020). Expression of CD47 and CALR in myeloproliferative neoplasms and myelodysplastic syndrome: Potential new therapeutical targets.. Journal of Clinical Oncology. 38(15_suppl). 7557–7557. 1 indexed citations
7.
Martinelli, Vincenzo, et al.. (2019). GATA‐1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis. Journal of Thrombosis and Haemostasis. 17(6). 896–900. 13 indexed citations
8.
Graham, Ciaren, et al.. (2014). GATA1 Is Overexpressed in Patients with Essential Thrombocythemia and It Is Normalized By Anagrelide Treatment. Blood. 124(21). 5574–5574. 1 indexed citations
9.
Baskaran, Vadsala, Amanda Goodwin, Lavanya Athithan, Ciro R. Rinaldi, & Alfredo Addeo. (2013). A Case of Abdominal Sarcoidosis in a Patient with Acute Myeloid Leukemia. SHILAP Revista de lepidopterología. 2013. 1–3. 2 indexed citations
10.
Benedetto, Giuseppe Di, et al.. (2013). BRAF Test and Cytological Diagnosis with a Single Fine Needle Cytology Sample. Acta Cytologica. 57(4). 337–340. 8 indexed citations
11.
Addeo, Alfredo, Ciro R. Rinaldi, & Miguel Panades. (2012). A Case of Small Cell Carcinoma of the Prostate and Review of the Literature. Tumori Journal. 98(3). e76–e78. 2 indexed citations
12.
13.
Laricchia‐Robbio, Leopoldo, et al.. (2009). EVI1 Impairs Myelopoiesis by Deregulation of PU.1 Function. Cancer Research. 69(4). 1633–1642. 61 indexed citations
14.
Camera, Andrea, Ciro R. Rinaldi, Salvatore Palmieri, et al.. (2008). Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Annals of Hematology. 88(2). 151–158. 18 indexed citations
15.
Senyuk, Vitalyi, et al.. (2007). Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis. Cancer Research. 67(12). 5658–5666. 50 indexed citations
16.
Rinaldi, Ciro R., Donglan Li, Rosanna Ciancia, et al.. (2007). GATA1 Is Over-Expressed in Essential Thrombocytemia. Blood. 110(11). 1534–1534.
17.
Tomaiuolo, Giovanna, Valentina Preziosi, M. Simeone, et al.. (2007). A methodology to study the deformability of red blood cells flowing in microcapillaries in vitro.. PubMed. 43(2). 186–92. 16 indexed citations
18.
Li, Donglan, Kislay K. Sinha, Maher Abdul‐Hay, et al.. (2007). RUNX1-RUNX1 Homodimerization Modulates RUNX1 Activity and Function. Journal of Biological Chemistry. 282(18). 13542–13551. 12 indexed citations
19.
Laricchia‐Robbio, Leopoldo, Donglan Li, Ciro R. Rinaldi, et al.. (2006). Point Mutations in Two EVI1 Zn Fingers Abolish EVI1-GATA1 Interaction and Allow Erythroid Differentiation of Murine Bone Marrow Cells. Molecular and Cellular Biology. 26(20). 7658–7666. 58 indexed citations
20.
Camera, Andrea, Marco Picardi, Marco Rossi, et al.. (2003). Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. The Hematology Journal. 4(5). 346–350. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Lambie Breakdown of academic impact, for papers by Monika J. Stankiewicz Breakdown of academic impact, for papers by Paulina M. H. van Strien Breakdown of academic impact, for papers by Mónica Ventura Ferreira Breakdown of academic impact, for papers by Cristina Robledo Breakdown of academic impact, for papers by Anke K. Bergmann Breakdown of academic impact, for papers by Katarina Reinhardt Breakdown of academic impact, for papers by Stephanie Wallner Breakdown of academic impact, for papers by Axel Karow Breakdown of academic impact, for papers by Jun Mo
Rankless by CCL
2026